Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNP-2198 for Helicobacter pylori eradication (Phase II, China)
CTR20220625Phase 2Completed
- Sponsor
- Dano Pharmaceuticals
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifasutenizol in Helicobacter pylori infection, sponsored by Dano Pharmaceuticals. Started Mar 2022; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on CTR20220625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220625.